Australians Move Closer To First Cloning License
This article was originally published in PharmAsia News
Stem cell researchers at Australia's Monash University moved closer to the possibility of receiving the first license from the government to clone human embryonic cells. The National Health and Medical Research Council held a meeting to consider proposals by Monash and the Australian Stem Cell Centre. If the license is granted, it would be the first since the nation's therapeutic-cloning law went into effect last year. The country also has in place strict guidelines for conducting such research, including a prohibition on implanting such cells into humans. (Click here for more
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.